SGLT2 inhibitors and GLP-1 receptor agonists are used in patients with type 2 diabetes as
glucose lowering therapies, with additional benefits of weight loss and blood pressure …

Diabetes mellitus (DM) is a metabolic disorder that occurs in the body because of decreased
insulin activity and/or insulin secretion. Pathological changes such as nephropathy …

Background Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and
glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the …

The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently
approved agent of this drug class, and the only GLP-1RA currently available as both …

Aim To investigate the effects of once‐weekly subcutaneous (sc) semaglutide 2.4 mg on
gastric emptying, appetite, and energy intake in adults with obesity. Materials and Methods A …

Background Semaglutide is an effective treatment for type 2 diabetes; however, 20–30% of
patients given semaglutide 1· 0 mg do not reach glycaemic treatment goals. We aimed to …

Introduction Obesity is frequently a comorbidity of type 2 diabetes. Even modest weight loss
can significantly improve glucose homeostasis and lessen cardiometabolic risk factors in …

Obesity is a growing epidemic within the USA. Because weight gain is associated with an
increased risk of developing life-threatening comorbidities, such as hypertension or type 2 …

Background Metabolic–bariatric surgery delivers substantial weight loss and can induce
remission or improvement of obesity-related risks and complications. However, more robust …

Semaglutide, a glucagon like peptide-1 (GLP-1) receptor agonist, is available as
monotherapy in both subcutaneous as well as oral dosage form (first approved oral GLP-1 …